Olumiant and Rinvoq Lawsuits
The FDA has issued a warning and forced the makers of Olumiant and Rinvoq to include additional warnings. The updated warnings highlight the serious health complications associated with taking these medications.
Kane & Silverman is no longer accepting Rinvoq and/or Olumiant cases at this time.
Here is everything you need to know about the Olumiant and Rinvoq lawsuits:
What Are Olumiant And Rinvoq?
Both Olumiant and Rinvoq are classified as Janus kinase (JAK) inhibitors. Janus kinase inhibitors work by blocking the activity of one or more of the Janus kinase family of enzymes. In blocking the enzymes, JAK inhibitors are believed to be effective in treating a variety of inflammatory conditions.
Olumiant and Rinvoq are prescribed to treat certain medical conditions:
- rheumatoid arthritis
- atopic dermatitis
- ulcerative colitis
- psoriatic arthritis
Patients using Rinvoq or Olumiant can experience certain side effects. The side effects include but are not limited to:
- heart attacks
- myocardial infarction (MI)
- severe blood clots
- stroke — ischemic/due to a blood clot
- deep vein thrombosis (DVT)
- pulmonary embolism (PE)
- arterial thrombosis
Olumiant And Rinvoq Lawsuits
The FDA reviewed clinical trial data and found increased risks for serious undisclosed side effects. Increased blood clots, cancer, and death have been made public as the FDA warns patients of the risks. Lawsuits are being filed on behalf of patients and their loved ones.
What Are Grounds For A Lawsuit?
If you want to file a legal claim against Olumiant or Rinvoq, it is important to know if you have grounds for a successful lawsuit. Most successful dangerous medication lawsuits often focus on a failure to warn and/or defective design.
Failure To Warn
In the United States, medications include warnings for possible side effects. Knowing about possible side effects lets people decide if the possible benefit is worth the risk of side effects.
A failure to warn of possible dangers gives the patient a false sense of safety. Patients taking Olumiant or Rinvoq before the label included blood clot, cancer, and heart attack warnings may qualify under a failure to warn claim.
A defective design claim involves medications that are unreasonably dangerous when used as directed. With the long-term use of medications, the effects of defective design are compounded. Patients that suffered health problems related to long-term use of these medications may qualify under a defective design claim.
When a loved one dies, the surviving family may be able to file a wrongful death claim. If a loved one died of complications associated with taking Olumiant or Rinvoq, you may be able to file a wrongful death claim.
Call An Injury Attorney
If you believe you or a loved one were harmed while taking Olumiant or Rinvoq, you may have a legal claim. Contact a personal injury attorney at Kane & Silverman to discuss the details of your case for free. You don’t pay us anything unless we recover money for your claim.